AQR Capital Management
CTMX icon

AQR Capital Management’s CytomX Therapeutics CTMX Stock Holding History

AQR Capital Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-391,860
Closed -$717K – 2225
2022
Q2 		$717K Buy
+391,860
New +$750K ﹤0.01% 1545
2021
Q4 		– Sell
-17,486
Closed -$89K – 2213
2021
Q3 		$89K Sell
17,486
-116,799
-87% -$625K ﹤0.01% 2206
2021
Q2 		$850K Buy
134,285
+33,277
+33% +$259K ﹤0.01% 1656
2021
Q1 		$781K Sell
101,008
-22,921
-18% -$181K ﹤0.01% 1660
2020
Q4 		$812K Buy
123,929
+1,937
+2% +$13.8K ﹤0.01% 1594
2020
Q3 		$811K Sell
121,992
-68,333
-36% -$507K ﹤0.01% 1528
2020
Q2 		$1.58M Buy
190,325
+49,986
+36% +$464K ﹤0.01% 1274
2020
Q1 		$1.08M Buy
140,339
+8,781
+7% +$61.2K ﹤0.01% 1317
2019
Q4 		$1.09M Buy
131,558
+76,900
+141% +$519K ﹤0.01% 1481
2019
Q3 		$403K Buy
54,658
+16,201
+42% +$160K ﹤0.01% 1824
2019
Q2 		$431K Buy
38,457
+16,356
+74% +$171K ﹤0.01% 1778
2019
Q1 		$238K Buy
22,101
+3,482
+19% +$51.5K ﹤0.01% 2037
2018
Q4 		$281K Sell
18,619
-13,871
-43% -$206K ﹤0.01% 1984
2018
Q3 		$601K Sell
32,490
-8,723
-21% -$199K ﹤0.01% 1888
2018
Q2 		$942K Sell
41,213
-4,499
-10% -$115K ﹤0.01% 1744
2018
Q1 		$1.3M Sell
45,712
-49,675
-52% -$1.42M ﹤0.01% 1562
2017
Q4 		$2.01M Buy
95,387
+42,751
+81% +$886K ﹤0.01% 1379
2017
Q3 		$956K Buy
52,636
+38,925
+284% +$607K ﹤0.01% 1697
2017
Q2 		$213K Buy
+13,711
New +$207K ﹤0.01% 2114

Other funds holding CTMX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

AQR Capital Management's CTMX Position: Q3 2022 in Review

AQR Capital Management sold out of CytomX Therapeutics (CTMX) in Q3 2022, closing a stake of 391,860 shares — an estimated $717K sold.

AQR Capital Management first reported a position in CTMX in Q2 2017 and held it in 19 quarters. The position peaked at $2.01M in Q4 2017. 84 funds tracked by Wall St. Rank hold CTMX as of Q3 2022.

  • AQR Capital Management reported no remaining CytomX Therapeutics position as of Q3 2022 after selling out during the quarter.
  • AQR Capital Management sold 391,860 CytomX Therapeutics shares in Q3 2022, an estimated $717K.
  • AQR Capital Management first reported a position in CytomX Therapeutics in Q2 2017 and held it in 19 quarters.
  • AQR Capital Management's CytomX Therapeutics position peaked at $2.01M in Q4 2017.
  • 84 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2022.

Based on AQR Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.